Werewolf Therapeutics (HOWL) Research & Development (2020 - 2026)
Werewolf Therapeutics (HOWL) posted quarterly Research & Development of $6.2 million for Q2 2026, down 53.12% year-over-year from $13.1 million in Q2 2025, and down 24.68% on a QoQ basis from $8.2 million in Q1 2026.
Werewolf Therapeutics (HOWL) Research & Development (2020 - 2026) Analysis & Trends
Werewolf Therapeutics has reported Research & Development for 7 years, with the latest figure at $6.2 million in Q2 2026.
- Research & Development for Q2 2026 came in at $6.2 million, down 53.12% year-over-year; the trailing twelve-month figure through Jun 2026 was $32.9 million (down 39.63% YoY), and the FY2025 annual result was $44.8 million, down 20.56% from the prior year.
- Research & Development slipped to $6.2 million in Q2 2026, from $8.2 million in the prior quarter.
- Over five years, Research & Development peaked at $15.9 million in Q4 2022 and troughed at $6.2 million in Q2 2026.
- A 5-year average of $11.7 million and a median of $12.1 million in 2023 frame the typical range for Research & Development.
- The widest annual swing landed in 2022, when Research & Development surged 127.22%; it then sank 55.92% in 2025.
- A 5-year view of Research & Development shows it stood at $15.9 million in 2022, then tumbled by 39.16% to $9.6 million in 2023, then jumped by 62.99% to $15.7 million in 2024, then sank by 55.92% to $6.9 million in 2025, then slipped by 11.12% to $6.2 million in 2026.
- Per Business Quant data, the three most recent Research & Development figures were $6.2 million in Q2 2026, $8.2 million in Q1 2026, and $6.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Werewolf Therapeutics | 20.90 Mn | 20.90 Mn | - | 6.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.16 Mn |
| Mar 31, 2026 | 8.18 Mn |
| Dec 31, 2025 | 6.93 Mn |
| Sep 30, 2025 | 11.63 Mn |
| Jun 30, 2025 | 13.14 Mn |
| Mar 31, 2025 | 13.12 Mn |
| Dec 31, 2024 | 15.73 Mn |
| Sep 30, 2024 | 12.53 Mn |
| Jun 30, 2024 | 15.27 Mn |
| Mar 31, 2024 | 12.91 Mn |
| Dec 31, 2023 | 9.65 Mn |
| Sep 30, 2023 | 10.84 Mn |
| Jun 30, 2023 | 9.58 Mn |
| Mar 31, 2023 | 11.71 Mn |
| Dec 31, 2022 | 15.86 Mn |
| Sep 30, 2022 | 13.07 Mn |
| Jun 30, 2022 | 13.89 Mn |
| Mar 31, 2022 | 10.95 Mn |
| Dec 31, 2021 | 13.40 Mn |
| Sep 30, 2021 | 9.79 Mn |